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Abstract
Background: The extravasation of granulocytes (such as neutrophils) at a site of inflammation is a key aspect of the
innate immune system. Signals from the site of inflammation upregulate granulocyte adhesion to the endothelium
to initiate extravasation, and also enhance granulocyte adhesion to extracellular matrix proteins to facilitate
granulocyte movement through the inflamed tissue. During the resolution of inflammation, other signals inhibit
granulocyte adhesion to slow and ultimately stop granulocyte influx into the tissue. In a variety of inflammatory
diseases such as acute respiratory distress syndrome, an excess infiltration of granulocytes into a tissue causes
undesired collateral damage, and being able to reduce granulocyte adhesion and influx could reduce this damage.
Results: We found that serum amyloid P (SAP), a constitutive protein component of the blood, inhibits granulocyte
spreading and granulocyte adhesion to extracellular matrix components. This indicates that in addition to
granulocyte adhesion inhibitors that are secreted during the resolution of inflammation, a granulocyte adhesion
inhibitor is present at all times in the blood. Although SAP affects adhesion, it does not affect the granulocyte
adhesion molecules CD11b, CD62L, CD18, or CD44. SAP also has no effect on the production of hydrogen peroxide
by resting or stimulated granulocytes, or N-formyl-methionine-leucine-phenylalanine (fMLP)-induced granulocyte
migration. In mice treated with intratracheal bleomycin to induce granulocyte accumulation in the lungs, SAP
injections reduced the number of granulocytes in the lungs.
Conclusions: We found that SAP, a constitutive component of blood, is a granulocyte adhesion inhibitor. We
hypothesize that SAP allows granulocytes to sense whether they are in the blood or in a tissue.
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Background
Infections or injuries to tissues such as the lungs cause
the damaged cells to recruit immune cells, including
granulocytes and monocytes, to the injury site [1,2]. The
transmigration of granulocytes such as neutrophils to
the site of injury or infection requires the interaction
of neutrophils with endothelial cells and extracellular
matrices [1,3,4]. In blood vessels, neutrophils are gene-
rally quiescent, but after an injury or infection, neutro-
phils begin to tether and roll on the blood vessel using
the selectin family of adhesion molecules such as
CD62L, CD62P, and P-selectin glycoprotein ligand-1
(PSGL-1) [5-7]. These adhesion molecules interact with
endothelial cell adhesion molecules such as E-selectin,
P-selectin, and PSGL-1 [5-7]. Activated endothelial cells
also interact with neutrophil glycoproteins such as CD44
and CD43 through E-selectin to slow neutrophil rolling
[5,8]. CD44 interacts with E-selectin and causes the redistri-
bution of PSGL-1 or L-selectin on rolling neutrophils,
which then promotes the tethering of neutrophils and slows
downthe rolling velocity [5]. The slow neutrophil rolling
allows neutrophils to sense signals such as interleukin
(IL)-8, tumor necrosis factor (TNF)α, granulocyte macro-
phage colony-stimulating factor (GM-CSF), or N-formyl-
methionine-leucine-phenylalanine (fMLP) from damaged
cells or infection [5,9-13], and activate integrin adhesion
molecules such as CD11b and CD18 [6,7,9,14-16]. IL-8 is
a neutrophil chemoattractant that can induce neutrophil
degranulation and enhance neutrophil production of re-
active oxygen species [9,16]. TNFα and GM-CSF increase
neutrophil adherence, release of reactive oxygen species,
and phagocytosis [10-13]. fMLP resembles bacterial waste
products, and activates neutrophil chemotaxis [17-20].
The upregulation of the adhesion molecules CD11b and
CD18 let neutrophils interact with endothelial ligands
such as intercellular adhesion molecule 1 (ICAM-1),
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which causes neutrophils to firmly adhere to the endothe-
lium [7] and move through the blood vessel into an
injured site [15]. Integrin molecules such as CD11b and
CD18 can also bind to extracellular matrix components
such as fibronectin, fibrinogen, laminin, and collagen, and
this binding aids in the movement of neutrophils through
extracellular matrices [1,3,4]. Other integrin adhesion
molecules such as CD61 facilitate leukocyte migration,
but little is known about their roles in neutrophil migra-
tion. Once activated neutrophils are at injured sites, they
can release reactive oxygen species and proteases, and
then engulf bacteria and debris by phagocytosis [21,22].
In the normal resolution of wound healing, activated
granulocytes such as neutrophils undergo programmed
cell death, which prevents the release of reactive oxygen
species from the granulocytes, thereby preventing any cell
damage in the surrounding tissue [23]. Since activated
granulocytes can damage surrounding cells, cytokines
such as IL-4 and IL-10 inhibit excessive recruitment of
granulocytes into the site of injury [24-27]. IL-4 and IL-10
inhibit the production of IL-8 and the release of TNFα
and IL-1β, which in turn limits granulocyte accumulation
and activation [24,25,27]. Lipid mediators such as lipoxin
A4 (LXA4) and lipoxin B4 (LXB4) inhibit neutrophil re-
cruitment by reducing neutrophil adhesion to endothelial
cells and vascular permeability [28,29]. Other lipid media-
tors including D-series and E-series resolvins and protec-
tins also inhibit transendothelial migration of neutrophils
[30,31].
Secreted pentraxin proteins such as pentraxin-3 (PTX3)
and C-reactive protein (CRP) also limit neutrophil recruit-
ment to a site of injury [32-37]. PTX3 is a pentraxin that
is produced and released by monocytes, dendritic cells,
endothelial cells, and smooth muscle cells in response to
inflammatory signals such as IL-1β, TNFα, or Toll-like
receptor (TLR) agonists [38]. CRP is a pentraxin secreted
into the blood by the liver as an acute phase protein
in humans, and inhibits neutrophil adhesion and che-
motaxis on activated endothelial cells [33,36]. Neutrop
hils recognize the pentraxin family of proteins through
Fcγ receptors [39,40]. Neutrophils express high levels of
FcγRII (CD32) and FcγRIII (CD16), and express low or
undetectable levels of FcγRI (CD64) [41,42]. These recep-
tors bind to the Fc portion of IgG immunoglobulins [43]
or pentraxin proteins such as PTX3, CRP, and serum
amyloid P (SAP), and help in the opsonization and phago-
cytosis of bacteria or debris [44-47]. Serum amyloid P is a
pentraxin that is constitutively secreted into the blood by
the liver [44]. The circulating SAP levels are approxi-
mately 30 μg/ml in humans [48], and approximately
15 μg/ml in C57BL/6 mice [49]. SAP effectively inhibits
the differentiation of monocytes to fibrocytes [50,51]
through FcγRI and FcRγ [51]. In vivo, injections of SAP
significantly reduce bleomycin-induced pulmonary fibrosis
in mice and rats [52]. Although it has been reported that
SAP elicits antifibrotic activity by stimulating IL-10 [53], a
recent study has shown that highly purified SAP does not
stimulate IL-10 production [54].
Little is known about SAP’s interaction with granulo-
cytes, which have Fcγ receptors. Activated granulocytes
release reactive oxygen species such as hydrogen perox-
ide and superoxide anions through activation of NADPH
oxidase [55] to kill microbes such as bacteria. However,
excessive release of these cytotoxic products can further
damage an injured tissue. SAP appears to decrease neu-
trophil oxygen metabolism [56], but SAP has no effect
on the production of hydrogen peroxide by neutrophils
stimulated by digitonin, mistletoe lectin, or fMLP [57].
IL-8 is a chemoattractant, and SAP has been reported to
bind IL-8 [58]. In the presence of IL-8, SAP decreases
neutrophil binding to fibronectin coated plates [58].
However, in the absence of IL-8, SAP acts as a neutro-
phil chemoattractant and increases neutrophil adhe-
sion [58]. SAP increases the percentage of neutrophils
expressing adhesion molecules such as CD11b and
CD18 and the fibronectin receptor α5β1 [58]. In flow
chambers, SAP inhibits the binding of human neutro-
phils to TNFα-stimulated human umbilical vein endo-
thelial cells [59]. Since granulocytes can recognize SAP
through Fc receptors, and the reports of the regulation
of neutrophil adhesion by SAP seem inconsistent, we
examined the effect of SAP on granulocyte adhesion and
recruitment to sites of inflammation.
Materials and methods
Isolating peripheral blood mononuclear cells (PBMCs) or
granulocytes
Blood was collected from healthy adult volunteers with
specific approval from the Institutional Review Boards of
Rice University and Texas A&M University. Written
consent was received and all samples were deidentified
before analysis. PBMCs were isolated and incubated
in RPMI serum-free medium (SFM) as described previ-
ously [60]. Granulocytes were isolated from blood u-
sing Lympholyte-poly (Cedarlane Laboratories, Hornby,
Canada) following the manufacturer’s directions and
resuspended in RPMI-1640 (Sigma) or 2% bovine serum
albumin (BSA) (Fraction V, A3059, Sigma) in RPMI-
1640. To check the purity of the granulocytes, 100 μl of
the isolated granulocytes were analyzed by flow cytome-
try (Accuri Cytometers, Ann Arbor, MI, USA) using the
combination of forward scatter (correlates to cell size)
and side scatter (correlates to cell granularity). Isolated
granulocytes were larger and more granular than other
cells. As an additional check of granulocyte purity,
200 μl of 0.5 × 106 cells/ml granulocytes in 2% BSA-
RPMI was aliquoted into a well of an eight-well glass
chamber slides (Lab-Tek, Nalge Nunc International,
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Naperville, IL, USA) for 1 h at 37°C. After incubation,
150 μl of media was removed and the slide was spun at
400 g for 5 minutes using a cytospin centrifuge (Shandon,
Runcorn, UK). The cells were then fixed with 200 μl of 2%
paraformaldehyde (PFA) in phosphate-buffered saline
(PBS) for 15 minutes at room temperature. After the PFA
was removed, 400 μl of ice-cold methanol was added to
the wells for 1 h at 4°C to permeabilize the cells. After
gently removing the methanol, 400 μl of PBS was added to
the wells for 10 minutes at room temperature and then
gently pipetted out from the corner of the well. This was
repeated twice. The slide was then mounted with a 4',6-
diamidino-2-phenylindole (DAPI)-containing mounting
media (Vectashield, Vector Laboratories). Images of the
cells were captured on an Axioplan2 microscope (Zeiss)
with a CoolSNAP HQ digital camera (Photometrics,
Tucson, AZ, USA) and Metamorph software (Molecular
Devices, Dowington, PA, USA).
Production of human SAP or murine SAP
Human SAP (hSAP) was from Calbiochem (Calbiochem-
EMD Chemicals, Darmstadt, Germany). Commercial
human SAP was buffer exchanged with 20 mM sodium
phosphate buffer as described previously [60]. Human
SAP or murine SAP (mSAP) were also prepared from
commercially available human serum (Gemini, West
Sacramento, CA, USA) or murine serum (Gemini) using
calcium-dependent binding to phosphoethanolamine-
conjugated agarose as described previously [52]. Commer-
cial or purified SAP was stored at 1 mg/ml in 20 mM so-
dium phosphate buffer, pH 7.4 at −20°C.
Granulocyte spreading assay with cell debris
PBMCs at 1 × 106 cells/ml in SFM were lysed with a
Dounce homogenizer and a drill-driven Teflon pestle
(Thomas Scientific, Swedesboro, NJ, USA) at 300 RPM
for 60 strokes to make cell debris. Then, 100 μl of
PBMCs at 0.5 × 106 cells/ml were incubated in flat bot-
tom 96-well tissue culture plates (BD, Franklin Lakes,
NJ, USA) in the presence or absence of 100 μl of
undiluted debris at 37°C. After 7 days, the supernatants
were clarified by centrifugation at 10,000 g for 10 mi-
nutes. Supernatants were collected into Eppendorf tubes
and flash frozen with liquid nitrogen, and stored at −80°
C until further use. A total of 100 μl of 5 × 105 cells/ml
granulocytes were incubated in 20 μg/ml SAP in RPMI,
25% PBMC supernatant in RPMI, a mix of 25% PBMC
supernatant and 20 μg/ml SAP in RPMI, or in RPMI.
After 1 h, fields of granulocytes were photographed
using a phase-contrast microscope with a 20 × objec-
tive. Granulocytes and spread granulocytes were then
counted.
Granulocyte adhesion
Wells of flat bottom 96-well tissue culture plates (BD)
were precoated with 50 μl of 20 μg/ml bovine plasma
fibronectin (Sigma) in PBS or 20 μg/ml cellular human
foreskin fibroblast fibronectin (Sigma) in PBS for 1 h at
37°C. After removing the fibronectin, the wells were
washed three times with 200 μl of PBS and then blocked
with 200 μl of 2% BSA-PBS for 2 h at room temperature.
The wells were then washed three times with 200 μl of
PBS and once with 200 μl of 2% BSA-RPMI before ad-
ding granulocytes. A total of 500 μl of granulocytes at
1 × 106 cells/ml in 2% BSA-RPMI were incubated in an
Eppendorf tube (preincubated with 2% BSA-RPMI for
2 h at 37°C), and SAP (or an equal volume of buffer)
was added to a final concentration of 30 μg/ml for
30 minutes at 37°C. A total of 100 μl of 1 × 106 cells/ml
granulocytes was then incubated in the well of a 96-well
plate for 10 minutes at 37°C to allow granulocytes to set-
tle. Then, 1 μl of 10 μg/ml recombinant human TNFα
(Peprotech, NJ, USA) in 2% BSA-RPMI was then added
to the well and gently mixed by stirring with the pipette
tip. After a 30-minute incubation with TNFα at 37°C,
non-adherent granulocytes were removed and the wells
were washed three times by pipetting in and then re-
moving 100 μl of 37°C PBS. The plate was then air dried,
stained with methylene blue and eosin (Richard-Allan
Scientific, Kalamazoo, MI, USA) [61], and the number of
adherent granulocytes was counted in five different
900 μm diameter fields of view. For assays on dry fibro-
nectin, the granulocytes adhesion was carried out as
above except the plates were air dried after blocking
with BSA.
Staining for granulocyte adhesion molecules
A total of 500 μl of granulocytes at 2.0 × 106 cells/ml
were aliquoted into Eppendorf tubes (precoated with 2%
BSA-RPMI for 1 h at 37°C) and incubated with 10 ng/ml
or 1 ng/ml TNFα, 100 ng/ml IL-8, or 10 ng/ml or 1
ng/ml GM-CSF in the presence or absence of 10 μg/ml
or 60 μg/ml SAP for 1 h at 37°C. For the granulocytes
that were stained with (anti-human) anti-CD18, anti-
CD61, or anti-CD44, SAP was added to 30 μg/ml. Cells
were then washed with ice-cold PBS, collected by centri-
fugation at 500 g for 5 minutes, and resuspended in 1 ml
of 4% BSA-PBS. Cells were stained in BSA-coated tubes
with 5 μg/ml antibodies against CD11b (BioLegend, San
Diego, CA, USA), CD62L (BD Biosciences), CD32 (BD
Biosciences), CD18 (BioLegend), CD61 (BD Biosciences),
CD44 (BD Biosciences), or mouse IgG1 isotype control
(BioLegend) for 30 minutes at 4°C. The cells were then
washed three times in ice-cold PBS, and incubated with
2.5 μg/ml fluorescein isothiocyanate (FITC)-conjugated
F(ab0)2 goat anti-mouse IgG antibodies (crossadsorbed
against human Ig, Southern Biotechnology, Birmingham,
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AL, USA) as described previously [60,62]. The cells were
washed three times in ice-cold PBS, resuspended in
200 μl 4% BSA-PBS, and analyzed by flow cytometry.
Hydrogen peroxide production
Wells of black 96-well cell culture plates (Nalge Nunc,
Rochester, NY, USA) were precoated with 50 μl of
20 μg/ml plasma fibronectin for 1 h at 37°C. The fibro-
nectin was then removed, and the wells were washed
three times with 200 μl of PBS, and then washed once
with Krebs-Ringer phosphate glucose buffer (KRPG)
(145 mM NaCl, 4.9 mM KCl, 0.54 mM CaCl2, 1.2 mM
MgSO4, 5.8 mM sodium phosphate, and 5.5 mM glu-
cose, pH 7.35) [11]. A total of 500 μl of granulocytes at
1.5 × 106 cells/ml in KRPG were incubated in an Eppen-
dorf tube (preincubated with 2% BSA-KRPG for 2 h at
37°C) and SAP was added to a final concentration of
30 μg/ml. As a control, a similar tube had an equal vo-
lume of buffer added to it. These were incubated for
30 minutes at 37°C. An assay mixture of 100 μl of
KRPG, 20 μl of 300 μM scopoletin (Sigma) in KRPG,
20 μl of 10 mM NaN3 in KRPG, and 20 μl of 10 U/ml
horseradish peroxidase (Sigma) in KRPG were aliquoted
into a well and the plate was equilibrated to 37°C for
5 minutes as described previously [11,63]. Then, 20 μl of
granulocytes incubated with or without 30 μg/ml SAP
was added to the assay mixture in the presence or
absence of 20 μl of 1 μg/ml TNFα in KRPG, 20 μl of
1 μM fMLP (Sigma) in KRPG, 20 μl of 1 μM phorbol
12-myristate 13-acetate (PMA) (Sigma) in KRPG, 20 μl
of 1 μM phorbol 12,13-dibutyrate (PDBu) (Sigma) in
KRPG, or 20 μl of KRPG. The 96-well plate was incu-
bated at 37°C and the fluorescence (excitation: 360 nm
emission: 460 nm) was monitored every 10 minutes for
3 h using a Synergy MX plate reader (BioTek, Winooski,
VT, USA).
Transmigration of granulocytes
A total of 50 μl of granulocytes at 1 × 106 cells/ml in 2%
BSA-RPMI was added to the top chamber of a 3 μm
pore size nylon membrane insert in a 24 well plate (BD)
in the presence or absence of 10 nM fMLP, 30 μg/ml
SAP, 10 nM fMLP and 30 μg/ml SAP or an equal vo-
lume of buffer in 2% BSA-RPMI. The bottom chambers
contained 600 μl of 10 nM fMLP in 2% BSA-RPMI,
600 μl of 30 μg/ml SAP in 2% BSA-RPMI, 600 μl of 10
nM fMLP and 30 μg/ml SAP in 2% BSA-RPMI, or equal
volumes of buffer in 2% BSA-RPMI. The transmigration
was carried out for 2 h at 37°C. The top chamber was
removed, and the granulocytes that had migrated into
the bottom chamber were then counted with a flow
cytometer.
Staining for apoptotic granulocytes
A total of 500 μl of granulocytes at 2.0 × 106 cells/ml
were aliquoted into Eppendorf tubes (precoated with 2%
BSA-RPMI for 1 h at 37°C) and incubated with 10 ng/ml
or 1 ng/ml TNFα, or 10 ng/ml or 1 ng/ml GM-CSF in
the presence or absence of 60 μg/ml SAP for 22 h at
37°C. The cells were then washed with ice-cold PBS, col-
lected by centrifugation at 500 g for 5 minutes, and
resuspended in 1 ml of 4% BSA-PBS. Cells were stained
with 5 μg/ml Alexafluor 488-conjugated annexin V
(Invitrogen) for 30 minutes at 4°C. The cells were then
washed three times in ice-cold PBS, resuspended in
200 μl 4% BSA-PBS, and analyzed with a flow cytometer.
Murine granulocyte adhesion assay
C57/BL6 mice (4 weeks old; Jackson Laboratories, Bar
Harbor, ME, USA) were housed at the Laboratory Animal
Resources and Research facility at Texas A&M University.
Animal procedures were approved by the Institutional
Animal Care and Use Committee at Texas A&MUniversity.
Mice were killed and blood was obtained via cardiac punc-
ture. From two to three mice, a total of 2 to 3 ml of blood
was collected in an ethylenediaminetetra-acetic acid
(EDTA)-containing vacutainer tube (BD) and the red
blood cells (RBC) in 2 ml of blood were lysed by adding
1 ml of ammonium chloride/potassium bicarbonate
(ACK) lysis buffer (15 mM NH4Cl, 1 mM KHCO3,
0.01 mM Na2EDTA) and incubating for 3 minutes at
room temperature. Cells were collected by centrifugation
at 500 g for 5 minutes at room temperature. The pellets
were resuspended in 200 μl PBS, and 1 ml ACK lysis buf-
fer was added. After 3 minutes, cells were collected by
centrifugation. This was then repeated two additional
times. Cells were resuspended in 1 ml PBS and then col-
lected by centrifugation. The cells were then resuspended
in 1 ml of 2% BSA-RPMI. Wells of flat bottom 96-well tis-
sue culture plates (BD) were precoated with 50 μl of
20 μg/ml plasma fibronectin (Sigma) in PBS for 1 h
at 37°C. A granulocyte adhesion assay was carried out in
2% BSA-RPMI similar to the human granulocyte adhesion
assay using 60 μg/ml human SAP instead of 30 μg/ml.
The adhered cells were stained for Ly6G to distinguish
granulocytes from other cell types as described previ-
ously [64]. The number of adhered Ly6G-positive granulo-
cytes was then counted as described above.
Granulocyte influx in mice
C57/BL6 mice (4 weeks old; Jackson) were treated with
an oropharyngeal aspiration of 50 μl of 0.2 U/kg or 3
U/kg bleomycin (Calbiochem) [65]. The successful aspi-
ration of bleomycin into the lungs was confirmed by lis-
tening to the crackling noise heard after the aspiration.
At 24 and 48 h following bleomycin aspiration (days 1
and 2), mice were given an intraperitoneal injection of
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50 μl of 1 mg/ml hSAP or 1 mg/ml mSAP in 20 mM
sodium phosphate buffer or an equal volume of 20 mM
sodium phosphate buffer. Mice were killed at day 3 after
bleomycin aspiration, and the lungs were perfused with
400 μl of PBS three times to collect cells by bronchoalveo-
lar lavage (BAL) as described previously [66]. The cells
were collected by centrifugation at 500 g for 5 minutes,
and the supernatants were transferred to Eppendorf tubes.
The pooled supernatants were flash frozen with liquid ni-
trogen, and stored at −80°C until further use. The cells
collected from BAL were resuspended in 100 μl of 4%
BSA-PBS and counted with a hemacytometer. The cells
were then diluted in a total volume of 600 μl of 4% BSA-
PBS. Then, 100 μl of diluted cells were aliquoted into cytos-
pin funnels and were spun onto glass slides (Superfrost
plus white slides, VWR, West Chester, PA, USA) at 400 g
for 5 minutes using a cytospin centrifuge (Shandon, Chesh-
ire, UK). These cells were then air dried, and stained with
5 μg/ml anti-mouse Ly6G (BioLegend) as previously
described [64]. After staining the cells, the number of cells
positive for Ly6G per 200 cells was counted. The percen-
tage of positive cells was then multiplied by the total num-
ber of cells recovered from the BAL to obtain the number
of granulocytes in the BAL. The mice were used in accor-
dance with guidelines published by the National Institutes
of Health, and the protocol was approved by the Texas
A&M University Animal Use and Care Committee.
Immunohistochemistry
After BAL, lungs were inflated with prewarmed optimal
cutting temperature (OCT) compound (VWR) and then
embedded in OCT, frozen on dry ice, and stored at −80°C
as described previously [52]. Lung tissue sections (6 μm)
were prepared and immunohistochemistry was performed
as described previously [52] except slides were incubated
with 2.5 μg/ml primary antibodies in 4% BSA-PBS for
60 minutes. The lung sections were stained for Ly6G (Bio-
Legend) to detect granulocytes, CD11b (BioLegend) to de-
tect macrophages, and CD45 (BioLegend) to detect all
leukocytes. Isotype-matched mouse irrelevant antibodies
were used as controls. Slides were then washed three
times with PBS over 30 minutes and incubated with
1.25 μg/ml biotinylated mouse F(ab’)2 anti-rat IgG in 4%
BSA-PBS for 30 minutes. Slides were then washed three
times in PBS over 30 minutes and incubated with a 1:500
dilution of streptavidin alkaline phosphatase (Vector La-
boratories) in 4% BSA-PBS for 30 minutes. Staining was
developed with a VectorRed Alkaline Phosphatase Kit
(Vector Laboratories) for 10 minutes. Slides were then
mounted as described previously [52].
Statistics
Statistical analysis was performed using Prism (GraphPad
Software, San Diego, CA, USA). Statistical significance was
determined using either analysis of variance (ANOVA) or
t test, and significance was defined as P < 0.05.
Results
Characterization of isolated granulocytes
Human granulocytes were isolated with lympholyte poly.
This isolation technique generated 80 ± 2% pure granu-
locytes, with small particulate matter accounting for
much of the contamination (Figure 1A). The number of
non-granulocyte cells was significantly lower than the
number of granulocytes obtained (Figure 1B). When iso-
lated cells were further analyzed for their nuclear
morphology using DAPI staining, the number of granu-
locytes was significantly more than the number of non-
granulocyte cells (Figure 1C,D). Eosin/methylene blue
staining of the isolated granulocytes indicated that there
were consistently less than 4% eosinophils and no de-
tectable basophils, with the majority of the cells neutro-
phils (D Pilling, Texas A&M University, College Station,
Texas USA, personal communication). These results
suggest that lympholyte poly effectively isolates granulo-
cytes from whole blood.
SAP inhibits granulocyte spreading
Granulocyte spreading allows granulocytes to polarize and
migrate towards the site of injury [67]. To determine the
effect of SAP on granulocyte spreading, human PBMCs
were incubated with cell debris. The PBMC supernatant
(which should contain cell debris as well as PBMC-
derived signals elicited in response to debris) was added to
human granulocytes in the presence or absence of SAP.
We observed spreading granulocytes in the controls,
which could have been an effect of laying granulocytes di-
rectly on a plastic tissue culture plate (Figure 2A). SAP
appeared to decrease granulocyte spreading (Figure 2A).
PBMC supernatant increased the numbers of spreading
granulocytes (Figure 2A,B), and the addition of SAP inhi-
bited the PBMC supernatant-induced granulocyte sprea-
ding (Figure 2B). These results suggest that SAP inhibits
granulocyte spreading.
SAP inhibits human granulocyte adhesion
TNFα increases the adherence of granulocytes on a va-
riety of extracellular matrices [11,68]. Since SAP inhi-
bited granulocyte spreading, we examined the effect of
SAP on granulocyte adhesion. Human granulocytes were
incubated with or without SAP, and were then incubated
with or without TNFα in plates precoated with plasma
fibronectin, cellular fibronectin, BSA, or air-dried cellu-
lar fibronectin. As observed previously, incubation with
TNFα increased the number of granulocytes that adhered
to the wells (Figure 3A-D). In the absence of TNFα, SAP
decreased the number of adhered granulocytes to 43.0 ±
7.4% compared to the control (mean ± SEM, n = 23,
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Figure 1 Characterization of isolated granulocytes. (A) Flow cytometry showing forward-scatter (x-axis) and side-scatter characteristics (y-axis)
from 10,000 events. The P2 area shows the granulocyte population. (B) The number of granulocytes isolated exceeds the number of other non-
granulocyte cells. The results are mean ± SEM of percentage total cells (n = 3 separate experiments). (C) Human granulocytes were seeded on a
glass slide and spread by centrifugation. Cells were stained with 4',6-diamidino-2-phenylindole (DAPI) to visualize nuclei. Bar is 20 μm. (D) The
number of granulocytes was counted based on nuclear morphology. There were fewer non-granulocyte cells compared to the isolated
granulocytes. The results are mean ± SEM of percentage total cells (n = 3 separate experiments). ***P <0.001 (t test).
Figure 2 Serum amyloid P (SAP) inhibits granulocyte spreading. Human peripheral blood mononuclear cells (PBMCs) were isolated and
incubated in the presence of cell debris. After 7 days, the PBMC supernatant was removed. Human granulocytes were incubated in the presence
or absence of SAP, PBMC supernatant (cell debris), or the combination of PBMC supernatant and SAP for 1 h. (A) Fields of granulocytes were then
photographed. Arrows indicate spread granulocytes. All of the figures represent one of three separate experiments. Bar is 20 μm. (B) The
percentage of the granulocytes that were spread was then counted. Values are mean ± SEM, n = 3. **P <0.01 (one-way analysis of variance
(ANOVA), Tukey’s test).
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P <0.001 by t test) on plasma fibronectin and decreased
the number of adhered granulocytes to 64.1 ± 14.9 com-
pared to the control on cellular fibronectin (n = 5, P <0.05
by t test). However, in wells coated with BSA or air-dried
fibronectin, there was no significant difference between
control and SAP treatment. SAP significantly inhibited the
TNFα-induced adhesion of granulocytes to plasma fibro-
nectin, cellular fibronectin, BSA, and air-dried cellular
fibronectin (Figure 3A-D). These results suggest SAP inhi-
bits granulocyte adhesion on native cellular and plasma
fibronectin, and that SAP inhibits TNFα-induced granulo-
cyte adhesion on a wider variety of surfaces.
SAP inhibits murine granulocyte adhesion
Since we found that human SAP can inhibit human
granulocyte adhesion induced by TNFα, we examined
if human SAP could also inhibit murine granulocyte
adhesion. Murine granulocytes were incubated with or
without human SAP and TNFα in plates precoated with
plasma fibronectin. TNFα increased the number of
adhered granulocytes (Figure 4). In the absence of
TNFα, SAP had no significant effect on granulocyte ad-
hesion (Figure 4). However, SAP significantly inhibited
TNFα-induced granulocyte adhesion to plasma fibronec-
tin (Figure 4).
Figure 3 Serum amyloid P (SAP) inhibits granulocyte adhesion. (A) First, 96-well tissue culture plates were coated with plasma fibronectin.
Human granulocytes were treated with or without SAP and/or human tumor necrosis factor (TNF)α, incubated in the plate, and adhered
granulocytes were counted. Values are mean ± SEM, n = 23. (B) A similar assay was performed using plates coated with cellular fibronectin. Values
are mean ± SEM, n = 5. (C) A similar assay was performed using plates coated with bovine serum albumin (BSA). Values are mean ± SEM, n = 4. (D)
A similar assay was performed using plates coated with cellular fibronectin, and then air dried. Values are mean ± SEM, n = 3. *P <0.05, **P <0.01,
***P <0.001 (one-way analysis of variance (ANOVA), Tukey’s test).
Figure 4 Serum amyloid P (SAP) inhibits murine granulocyte
adhesion induced by tumor necrosis factor (TNF)α. First, 96-well
tissue culture plates were coated with plasma fibronectin. Crude
murine granulocytes were incubated with SAP and/or TNFα in the
plates, and adhered cells were stained for the granulocyte marker
Ly6G and counted. Values are mean ± SEM, n = 8. *P <0.05,
***P <0.001 (one-way analysis of variance (ANOVA), Tukey’s test).
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SAP has no effect on levels of some adhesion molecules
To determine how SAP affects adhesion, we analyzed
receptors such as CD11b and CD62L whose levels
change in activated granulocytes such as neutrophils.
Granulocytes were treated with TNFα, IL-8, or GM-CSF
in the presence or absence of SAP, and the cells were
stained for CD11b, CD62L, and CD32 (FcγRII) as a con-
trol. There was no significant effect of any treatment on
the number of CD11b-positive cells (Figure 5A). IL-8 in
the presence or absence of SAP had no effect on the
levels of CD11b or CD62L compared to untreated gra-
nulocytes (Figure 6A). As shown previously, TNFα and
GM-CSF induced increased levels of CD11b (Figure 6A)
[10,13,69], but SAP had no effect on the activation. As
observed previously, TNFα and GM-CSF decreased the
number and the levels of CD62L-positive cells, [70] but
SAP had no effect on the basal or stimulated CD62L
levels (Figures 5B and 6A). There was no significant
effect on the levels of CD32 or mouse IgG1 (control)
staining when granulocytes were treated with TNFα or
IL-8 in the presence or absence of SAP (Figures 5C, D
and 6B). Together, the data indicate that although TNFα
and GM-CSF alter levels of CD11b and CD62L on gran-
ulocytes [10,13,69,70], the addition of SAP has no obvi-
ous effect on the levels of these adhesion molecules or
CD32.
Since SAP had no effect on the levels of the surface
receptors CD11b or CD62L, we examined the levels of
Figure 5 Serum amyloid P (SAP) has no significant effect on the number of some surface receptors associated with granulocyte
activation. (A) Human granulocytes were treated with interleukin (IL)-8, granulocyte macrophage colony-stimulating factor (GM-CSF), or tumor
necrosis factor (TNF)α in the presence or absence of SAP. The cells were then stained for CD11b. Values are mean ± SEM, n = 3. (B) Granulocytes
were treated with GM-CSF or TNFα in the presence or absence of SAP. The cells were then stained for CD62L. Values are mean ± SEM, n = 3. (C)
Granulocytes were treated with IL-8 or TNFα in the presence or absence of SAP. The cells were then stained for CD32. (D) Granulocytes were
treated as in (C), and were then stained with mouse IgG1. The absence of an error bar indicates that the error was smaller than the line thickness.
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other adhesion molecules such as CD18, CD61, or CD44
[71]. As described previously, TNFα increased the levels
of CD18 and decreased levels of CD44 (Figure 7)
[10,72], but there was no significant effect of TNFα on
the levels of CD61. Similarly, fMLP slightly increased the
levels of CD18 (Figure 7) but there was no significant ef-
fect on the levels of CD61 or CD44. SAP had no effect
on the basal or stimulated levels of CD18, CD44, or
CD61. Together, the data indicate that although SAP
affects granulocyte adhesion, it does not affect cell sur-
face levels of CD11b, CD62L, CD18, CD61, or CD44.
SAP has no detectable effect on hydrogen peroxide
production
Activated granulocytes release hydrogen peroxide to kill
microbes such as bacteria [55], but excessive release of
hydrogen peroxide can further damage an injured tissue.
To examine whether SAP can inhibit the production of
hydrogen peroxide from unstimulated granulocytes or
granulocytes stimulated by TNFα, fMLP, PDBu, or PMA,
we examined the change in the fluorescence intensity of
scopoletin, a fluorescent molecule that gets modified by
hydrogen peroxide. To inhibit hydrogen peroxide con-
sumption by the granulocytes, this assay uses sodium
azide to inactivate myeloperoxidase and catalase, and
release the intracellular hydrogen peroxide to the me-
dia [73]. As previously observed, in control cells the
extracellular hydrogen peroxide levels increased with
time, which could have been the release of intracellular
hydrogen peroxide since sodium azide will result in the
leakage and release of intracellular hydrogen peroxide
[73]. Nevertheless, the production of hydrogen peroxide
when cells were treated with TNFα, fMLP, PDBu, or
PMA exceeded the production of hydrogen peroxide in
control cells (Figure 8). As previously observed, SAP had
no significant effect on the production of hydrogen pe-
roxide induced by fMLP (Figure 8A). In addition, SAP
had no significant effect on the production of hydro-
gen peroxide induced by TNFα (Figure 8B), PDBu
(Figure 8C), or PMA (Figure 8D). Together, the data in-
dicate that although SAP affects granulocyte adhesion, it
does not appear to affect granulocyte hydrogen peroxide
production.
Figure 6 Serum amyloid P (SAP) has no significant effect on the levels of CD11b, CD62L, or CD32. (A) Human granulocytes were treated
as in Figure 4A. The cells were then stained for CD11b or CD62L. Values are mean ± SEM of percentage of median fluorescence intensity of the
untreated (none) CD11b-positive or CD62L-positive cells (n = 3 separate experiments except n = 2 for interleukin (IL)-8 and IL-8 + SAP).
(B) Granulocytes were treated as in Figure 4C, and were then stained for CD32 or stained with a control mouse IgG1. Values are mean ± SEM of
percentage of median fluorescence intensity of the untreated (none) CD32-positive or mouse IgG1-positive cells.
Figure 7 Serum amyloid P (SAP) has no significant effect on
the levels of CD18, CD61, or CD44. Granulocytes pretreated with
or without SAP were incubated in the presence or absence of tumor
necrosis factor (TNF)α or N-formyl-methionine-leucine-phenylalanine
(fMLP). The cells were then stained for CD18, CD61, or CD44. Values
are mean ± SEM of median fluorescence intensity of positively
stained control cells (n = 3 for CD18 and CD61 and n = 2 for CD44).
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SAP has no detectable effect on the migration of
granulocytes
The formyl peptide fMLP induces the migration of gra-
nulocytes [74]. To determine the role of SAP in granulo-
cyte migration, we carried out migration assays using a
Boyden chamber. Granulocytes were placed on a porous
membrane and the bottom of the membrane touched
a solution containing buffer or fMLP in the presence or
absence of SAP. fMLP significantly increased the num-
ber of granulocytes that migrated across the porous
membrane, while SAP had no effect on the migration of
granulocytes or the migration of granulocytes caused by
fMLP (Figure 9).
SAP has no effect on the apoptosis of granulocytes
Phosphatidylserine gets exposed from the inner surface
of the plasma membrane during apoptosis where there
is loss of phospholipid asymmetry [75]. Annexin V is a
protein that binds to phosphatidylserine, and we can use
a fluorescent dye conjugated to annexin V to identify
apoptotic cells [76]. Granulocytes were treated with
TNFα or GM-CSF in the presence or absence of SAP, and
the cells were stained with Alexafluor 488-conjugated
annexin V. There was no significant effect on the percen-
tage of annexin V-stained cells in all of the conditions
except for the cells treated with 10 ng/ml GM-CSF
(Figure 10). GM-CSF-treated cells had a decreased per-
centage of annexin V-positive cells compared to other
conditions, which matches previous observations that
GM-CSF delays apoptosis of granulocytes such as neutro-
phils [77]. SAP had no significant effect on the percentage
Figure 8 Serum amyloid P (SAP) has no significant effect on the production of hydrogen peroxide induced by N-formyl-methionine-
leucine-phenylalanine (fMLP), tumor necrosis factor (TNF)α, phorbol 12-myristate 13-acetate (PMA), or phorbol 12,13-dibutyrate
(PDBu). (A) Granulocytes pretreated with or without SAP were treated with fMLP in the presence of scopoletin. The fluorescence intensity of
scopoletin was measured over 3 h, and after measuring the effect of different amounts of hydrogen peroxide on scopoletin fluorescence; this
was then converted to hydrogen peroxide production. Similar assays were performed using granulocytes stimulated with (B) TNFα, (C) PDBu, or
(D) PMA. All of the figures represent one of the three separate experiments for TNFα, fMLP, or PMA, or one of the two separate experiments for PDBu.
Figure 9 Serum amyloid P (SAP) has no significant effect on
the migration of granulocytes. Granulocytes were placed on a
porous membrane that touched a chamber containing buffer, N-
formyl-methionine-leucine-phenylalanine (fMLP), SAP, or fMLP and
SAP. Migration was carried out for 2 h at 37°C. A total of 25 μl of
granulocytes from the bottom chamber was counted with a flow
cytometer. The results are mean ± SEM of migrated granulocytes
(n = 4 separate experiments).
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of annexin V-positive cells under all tested conditions,
suggesting that SAP has no obvious effect on granulocyte
apoptosis.
SAP specifically inhibits the accumulation of Ly6G-positive
cells in lungs of mice treated with bleomycin
Since SAP inhibits granulocyte adhesion, we examined
the effect of SAP on bleomycin-induced granulocyte ac-
cumulation in the lungs of mice. Mice were treated with
or without 0.2 U/kg bleomycin on day 0 and were then
given intraperitoneal injections of SAP on days 1 and 2.
On day 3, the mice were killed and cells from the lungs
were collected by BAL. There was no statistically signifi-
cant difference in the number of cells collected from
BAL of control, saline, 0.2 U/kg bleomycin and buffer,
0.2 U/kg bleomycin and human SAP, or 0.2 U/kg bleo-
mycin and mouse SAP (Figure 11A). Cells collected from
the BAL of mice were then stained with anti-mouse Ly6G
(this stains neutrophils and some eosinophils) [78,79].
There was an increased number of Ly6G-positive cells in
the BAL from mice treated with 0.2 U/kg bleomycin and
buffer compared to the number of Ly6G-positive cells in
the BAL from control (untreated mice) or saline-treated
mice (Figure 11C). However, there was a decreased num-
ber of Ly6G-positive cells in the BAL from mice treated
with 0.2 U/kg bleomycin and human SAP or 0.2 U/kg
bleomycin and mouse SAP when compared to the BAL
from mice treated with 0.2 U/kg bleomycin and buffer
(Figure 11B,C). There was no significant difference bet-
ween the number of Ly6G-positive cells in the BAL from
mice treated with 0.2 U/kg bleomycin and human SAP or
0.2 U/kg bleomycin and mouse SAP when compared to
control (untreated mice) or saline-treated mice. We
stained lung sections with Ly6G after BAL to detect gra-
nulocytes remaining in the lungs after BAL. There was an
increased number of Ly6G-positive cells in the lung sec-
tions after BAL in mice treated with 0.2 U/kg bleomycin
and buffer compared to the number of Ly6G-positive cells
in the lung sections from control (untreated mice), saline-
treated mice, or mice treated with 0.2 U/kg bleomycin and
human SAP (Figure 11D,E).
We also similarly treated mice with 3 U/kg bleomycin.
Previous results from our laboratory have shown that
human SAP is more potent at inhibiting the differen-
tiation of monocytes to fibrocytes than mouse SAP [51],
so we decided to only use human SAP. There was no
statistically significant difference between the number of
cells collected from the BAL of control or saline-treated
mice (Figure 12A). However, there were an increased
number of cells collected in the BAL from mice treated
with 3 U/kg bleomycin and buffer or 3 U/kg bleomycin
and human SAP when compared to control or saline-
treated mice (Figure 12A). There was also an increased
number of Ly6G-positive cells in the BAL from mice
treated with 3 U/kg bleomycin and buffer when com-
pared to the number of Ly6G-positive cells in the BAL
from control or saline-treated mice (Figure 12B,C).
There was a decreased number of Ly6G-positive cells in
the BAL from mice treated with 3 U/kg bleomycin and
human SAP when compared to the number of Ly6G-
positive cells in the BAL from mice treated with 3 U/kg
bleomycin and buffer (Figure 12B,C). However, there
was no statistically significant difference in Ly6G-
positive cells in the BAL from mice treated with 3 U/kg
bleomycin and human SAP when compared to the
Ly6G-positive cells in the BAL from control or saline-
treated mice (Figure 12C). When lung sections were
stained with Ly6G after BAL to detect granulocytes
remaining in the lungs after BAL, there was an increased
number of Ly6G-positive cells in the lung sections of
mice treated with 3 U/kg bleomycin and buffer com-
pared to the number of Ly6G-positive cells in the lung
sections from control (untreated mice), saline-treated
mice, or mice treated with 3 U/kg bleomycin and human
SAP (Figure 12D,E).
For both 0.2 and 3 U/kg bleomycin followed by buffer
injections, there were more granulocytes observed in the
lung sections compared to the lung sections from the
bleomycin followed by human SAP treatment group
(Figures 11D,E and 12D,E). This indicates that if we had
been able to obtain all of the pulmonary granulocytes,
the difference between bleomycin/buffer injections and
bleomycin/SAP injections would have been even greater
than the differences shown in Figures 11C and 12C. We
further analyzed the lung sections for macrophages and
leukocytes using anti-CD11b (in mice, Cd11b is a macro-
phage marker) and anti-CD45 antibodies (Figure 13).
Figure 10 Serum amyloid P (SAP) has no effect on granulocyte
apoptosis. Granulocytes were treated with granulocyte macrophage
colony-stimulating factor (GM-CSF) (10 ng/ml or 1 ng/ml) or tumor
necrosis factor (TNF)α (10 ng/ml or 1 ng/ml) in the presence or
absence of SAP (60 μg/ml) for 22 h at 37°C. The cells were then
stained with annexin V and analyzed by flow cytometry. The results
are mean ± SEM of percentage positive cells (n = 3 separate
experiments).
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Figure 11 Serum amyloid P (SAP) decreases the accumulation of Ly6G-positive cells in 0.2 U/kg bleomycin-treated mouse lungs. Mice
were treated with 0.2 U/kg bleomycin using an oropharyngeal technique on day 0. Mice were then injected with either 50 μg SAP or an equal
volume of buffer on days 1 and 2. After the mice were killed on day 3, cells were collected by bronchoalveolar lavage (BAL). (A) The total number
of cells collected by BAL from mice with the indicated treatments. (B) Cells collected by BAL were stained with anti-mouse Ly6G to detect
granulocytes. Arrows indicate Ly6G-positive cells. Bars are 20 μm. (C) The total number of Ly6G-positive cells in the above experimental groups.
Values are mean ± SEM (n = 4 for control and mice treated with bleomycin and buffer, n = 5 for mice treated with saline and buffer or mice
treated with bleomycin and mouse SAP, and n = 6 for mice treated with bleomycin and human SAP). Using the non-parametric Mann–Whitney
two-tailed t test, there was an increased number of Ly6G-positive cells in the BAL from bleomycin and buffer when compared to control, mice
treated with saline and buffer, or mice treated with bleomycin and human SAP; *P <0.05. Using the non-parametric Mann–Whitney two-tailed t
test, there was no significant difference between mice treated with bleomycin and buffer or mice treated with bleomycin and mouse SAP.
However, using the non-parametric Mann–Whitney one-tailed t test, there was a statistically significant increase in the number of Ly6G-positive
cells in the BAL from mice treated with bleomycin and buffer when compared to the number of Ly6G-positive cells in the BAL from mice treated
with bleomycin and mouse SAP. (D) After obtaining cells by BAL, lung sections were stained with anti-mouse Ly6G to detect granulocytes.
Arrows indicate Ly6G-positive cells. Bars are 100 μm. (E) Counts of granulocytes in sections. Values are mean ± SEM, n = 3. *P <0.05 (t test).
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When lung sections were stained for CD11b or CD45,
there was no difference between CD11b-positive cells or
CD45-positive cells in the lung sections from mice treated
with 0.2 U/kg bleomycin and buffer or mice treated with
0.2 U/kg bleomycin and human SAP (Figure 13). Our
results therefore suggest that at 3 days, SAP has no effect
on the bleomycin-induced accumulation of macrophages
or other leukocytes in the lungs, but SAP reduces the
bleomycin-induced accumulation of granulocytes in the
lungs. However, SAP injections do reduce bleomycin-
induced leukocyte infiltration by day 14 or day 21 [52]. It
is possible that at an early injury stage, SAP only affects
Figure 12 Serum amyloid P (SAP) decreases the accumulation of Ly6G-positive cells in 3 U/kg bleomycin-treated mouse lungs. Mice
were treated with 3 U/kg bleomycin using an oropharyngeal technique on day 0. Mice were then injected with either 50 μg SAP or an equal
volume of buffer on days 1 and 2. After the mice were killed on day 3, cells were collected by bronchoalveolar lavage (BAL). (A) The total number
of cells collected by BAL from mice with the indicated treatments. (B) Cells collected by BAL were stained with anti-mouse Ly6G to detect
granulocytes. Arrows indicate Ly6G-positive cells. Bars are 20 μm. (C) The total number of Ly6G-positive cells in the above experimental groups.
Values are mean ± SEM (n = 4 for control, mice treated with bleomycin and buffer, or mice treated with bleomycin and human SAP, and n = 5 for
mice treated with saline and buffer); *P <0.05 (significant difference) as determined by non-parametric Mann–Whitney two-tailed t tests. (D) After
obtaining cells from BAL, lung sections were stained with anti-mouse Ly6G to detect granulocytes. Arrows indicate Ly6G-positive cells. Bars are
100 μm. (E) Counts of granulocytes in sections. Values are mean ± SEM, n = 3. *P <0.05, ***P <0.001 (t test).
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the infiltration of granulocytes, but at later injury stage,
SAP can inhibit the overall leukocyte infiltration induced
by bleomycin.
Discussion
We found that SAP inhibits cell debris-induced granulo-
cyte spreading and TNFα-induced granulocyte adhesion
on different extracellular matrices. However, SAP has no
effect on the surface levels of granulocyte adhesion
molecules such as CD11b, CD62L, CD18, or CD44 that
are affected by granulocyte activating factors such as
TNFα, GM-CSF, or fMLP. SAP also has no effect on the
production of hydrogen peroxide induced by granulocyte
activating factors such as PMA, PDBu, fMLP, or TNFα.
Figure 13 Serum amyloid P (SAP) has no effect on the accumulation of CD11b-positive cells or CD45-positive cells in 0.2 U/kg
bleomycin-treated mouse lungs. Cells from bronchoalveolar lavage (BAL) were further analyzed for the presence of CD11b-positive or CD45-
positive cells. (A) The total number of CD11b-positive cells in the cells collected from the BAL of mice treated with bleomycin and buffer or mice
treated with bleomycin and human SAP. (B) The total number of CD45-positive cells in the cells collected from the BAL of mice treated with
bleomycin and buffer or mice treated with bleomycin and human SAP. (C) After obtaining cells from BAL, lung sections were stained with anti-
mouse CD11b or CD45 to detect macrophages and leukocytes remaining in the lungs. Arrows indicate CD11b-positive or CD45-positive cells. Bars
are 100 μm.
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In addition, SAP did not have a significant effect on
fMLP-induced granulocyte migration. Nevertheless, in-
traperitoneal injections of SAP significantly reduced the
number of granulocytes that accumulate in the lungs of
mice treated with bleomycin.
A previous report found that SAP acts as a granu-
locyte chemoattractant, increases granulocyte adhesion,
and increases the percentage of granulocytes expres-
sing CD11b, CD18, and α5β1 [58]. However, a different
group found that SAP inhibits the binding of human
granulocyte to TNFα-stimulated human umbilical vein
endothelial cells [59]. In this report, we find that SAP
does not act as a granulocyte chemoattractant, tends to
decrease granulocyte adhesion, and does not affect the
percentage of granulocyte expressing CD11b and CD18.
Given that a variety of factors can activate granulocytes,
induce granulocyte chemotaxis and increase granulocyte
adhesion, we hypothesize that the SAP used in the first
report may have been contaminated with a small amount
of some material that activated the granulocytes.
Other pentraxin family proteins also inhibit granulo-
cytes such as neutrophil accumulation in animal models
of acute lung injury (ALI) or acute respiratory distress
syndrome (ARDS) [37]. CRP and PTX3 also decrease the
number of neutrophils that accumulate in injured lungs
[32,37]. CRP inhibits neutrophil adhesion and chemotaxis
[37]. Administering CRP intravenously 10 minutes before
the intratracheal instillation of the neutrophil chemotactic
agent C5a reduces neutrophil accumulation in lungs [35].
CRP inhibits L-selectin-mediated neutrophil adhesion on
TNFα activated endothelial cells by inducing L-selectin
shedding from neutrophils. CRP peptide 201–206 me-
diates the antiadhesive action through CD32 [33]. Both
native CRP and CRP peptide 201–206 prevent neutrophil
chemotaxis towards fMLP by inhibiting fMLP-induced
p38 mitogen-activated protein (MAP) kinase activity [36].
Similarly, pretreating mice intravenously with PTX3
reduces the number of neutrophils in acid-induced acute
lung injury in mice [32]. PTX3 deficiency also increases
the number of neutrophils in the lungs of mice treated
with lipopolysaccharide (LPS) [34]. PTX3 blocks the inter-
action of P-selectin glycoprotein ligand-1 (PSGL-1) on
neutrophils from interacting with P-selectin on the acti-
vated endothelial cells and causes neutrophil detachment
rather than arrest to prevent neutrophil migration [32].
An intriguing possibility is that the three pentraxins (SAP,
CRP, and PTX3) may use a common mechanism to inhibit
granulocytes such as neutrophil adhesion.
SAP prevents the accumulation of granulocytes in the
lungs of bleomycin-injured mice. Since SAP inhibits
granulocytes adhesion, it is probable that SAP reduces
the accumulation of granulocytes by dampening the
interaction of granulocytes with extracellular matrices.
We still do not know the granulocyte adhesion receptors
that are affected by SAP. One possibility is that SAP
affects β1 integrins such as α2β1, α5β1, α6β1, or α9β1
that are found on granulocytes and can recognize diffe-
rent extracellular matrices [80-83].
Conclusions
We found that SAP, a constitutive component of blood,
is a granulocyte adhesion inhibitor. Furthermore, we
found that injections of SAP decrease granulocyte le-
vels in the lungs in a murine model of ARDS. We
hypothesize that SAP allows granulocytes to sense
whether they are in the blood or in a tissue, and that in-
creasing serum SAP levels, for instance by injection,
may be a possible therapeutic for neutrophil-associated
diseases such as ARDS.
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